Sensai
Reading the tape…Pulling live market data…Setting the scene…
Sensai
AI Stock Dissection
AI Stock Dissection
TORNTPHARM
Mr. Aman Mehta · Ahmedabad, India · 18,258 employees
₹4,878.50
▼-0.40%Torntparm is a specialty pharmaceutical company experiencing strong revenue growth but trading at a premium valuation with moderate profitability.
Exchange
NSI
Currency
INR
Day range
₹4,857.20 – ₹4,949.00
52-week range
₹3,480.60 – ₹5,085.80
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
AI investment rating
AI analysis75% confidence
The stock appears overvalued relative to its P/E of 76.61, especially considering its profit margin of 15.48%, though strong revenue growth may justify some premium.
4.1% below the 1-year high · trend down
Hedge-fund memo
Today
The stock is down 0.40% today, trading near the lower end of its day range but above its 52-week low.
This week
The stock has shown moderate volatility this week, trading within a narrow range.
This month
The stock has been underperforming over the past month, trading below its 52-week high.
Bull thesis
Bear thesis
Hidden risks
News & sentiment
Neutral
6 headlines · 3 outlets · 7d
Tone · daily average
Smart money
Named holders aren't published for this listing (common for Indian stocks). The split at left is live.
Financial health
Profitability
Growth
Balance sheet
Financial statements
Earnings intelligence
Beat estimates in 2 of 4 recent quarters (EPS actual vs. consensus).
12.8537 vs 16.19
-20.61% surprise
19.001 vs 18.66167
1.82% surprise
17.7484 vs 17.474
1.57% surprise
Competitive landscape
| Company | Market cap | P/E | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| TORNTPHARM | 1.86T | 76.61 | 16.99% | 20.20% | 41.80% |
| ALKEM | 695.45B | 30.25 | 17.56% | 11.42% | 14.60% |
| APOLLOHOSP | 1.28T | 66.02 |
Technical intelligence
Volume
RSI (14) · 70 overbought / 30 oversold
MACD (12,26,9) · MACD vs signal
Candlesticks, volume, RSI and MACD from 500sessions of real Yahoo daily data. Moving averages use full history, so they're accurate at the left edge. Support / resistance are the 52-week low / high. Educational — technical signals are not buy or sell calls.
Risk intelligence
High debt-to-equity ratio
Mitigation: Focus on deleveraging through improved cash flows
Regulatory challenges in pharmaceutical industry
Mitigation: Diversify product portfolio and geographies
Business intelligence
Competitive moat
The company has established a niche in specialty pharmaceuticals with a focus on quality and regulatory compliance, creating barriers to entry.
Supply chain
Upstream (inputs / suppliers)
↓
Downstream (customers / markets)
M&A / strategic moves
Catalyst calendar
New product launches
Geographic expansion
Thesis builder
Bull case
Strong revenue growth and expanding market presence could drive further upside despite high valuation.
Base case
The company maintains steady profitability with moderate growth, trading at a premium justified by its specialty focus.
Bear case
High valuation combined with debt levels could lead to correction if growth slows.
Time horizon
12-18 months
Est. CAGR
15-20%
Entry (qual.)
Consider on dips below 4500 INR for better risk-reward ratio
Exit (qual.)
Take profits above 5000 INR or if growth momentum significantly weakens
Overall conviction 75%
Knowledge graph
Executives & sector are live; peers are clickable → their dissection. Institutional holders shown where the exchange publishes them.
Portfolio impact
Enter tickers + weights, then see how TORNTPHARM fits.
Scenario simulator
Simulate a macro shock and see the illustrative impact:
Tailwind for tech & enablers.
Illustrative impact
Medium prob.Directional illustration only — not modelled on this company's actuals. A real simulator needs company financials.
Explain like…
Re-explain TORNTPHARM for a different audience:
Pick a persona to get a tailored explanation.
Sensai publishes educational market commentary, not investment advice. We are not SEBI-registered investment advisers or research analysts, and nothing here is a recommendation to buy, sell, or hold any security.
Live prices, index levels, and other market data are pulled from third-party feeds, may be delayed, and can be inaccurate or unavailable. Do not rely on them for trading decisions.
Investing in equities carries risk, including the loss of principal. Always do your own research and consider consulting a SEBI-registered adviser before making any investment decision.
Hidden opportunities
Watch next
The stock is attractive for growth investors but may be too expensive for value seekers at current levels.
TradingView·1d ago·integration milestone reached
TradingView·3d ago·stock price increases
TradingView·4d ago·neutral financial data
equitypandit.com·6d ago·weekly outlook unclear
TradingView·6d ago·stock price decreases
LatestLY·6d ago·unrelated stock picks
Real press coverage from the last 7 days, scored by AI for tone — click any headline for the source. This is news sentiment, not social: X / Reddit / Telegram scoring needs a paid social provider. Educational only.
Annual income statement, oldest → newest. Live via Yahoo.
16.19 vs 17.2875
-6.35% surprise
| 21.50% |
| 11.91% |
| 18.10% |
| AUROPHARMA | 906.97B | 26.15 | 9.93% | 14.94% | 5.60% |
Peers via Yahoo's similarity graph, same-sector first; fundamentals live. Ask the AI copilot below for a qualitative head-to-head.
Support (day/52w low)
₹4,857.20
Resistance (day/52w high)
₹4,949.00
Volume
7,76,536
Trend
down
RSI (14)
49
MACD
bearish
MA cross
golden
50-day MA
₹4,647.82
200-day MA
₹4,180.67
vs 200-DMA
16.7%
RSI/MACD computed from 6 months of daily closes; moving averages from Yahoo. Options positioning still needs an options feed.